A Phase 1 interventional study of TD-1211 Dose 1 and TD-1211 Dose 2 in Constipation, sponsored by Glycyx Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Glycyx Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 345 studies in Constipation with a site in United States — 27 open to participants now, 38 under way, 5 of them phase 3. Constipation · United States.
Among the 345 studies in Constipation with a site in United States, this one is the 212th largest by enrollment of the 307 interventional ones that give a count, is one of 18 that started in 2012, is one of 18 in phase 1, and was the 132nd registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →27 of the 345 studies in Constipation with a site in United States are open now. Recruiting first, the newest first:
Radicle Science · Sites in United States
Ages 21–105 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Belgium, Canada and 5 more countries
Ages 18–75
Peach Perfect · Sites in United States
Ages 18–60
Ardelyx · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
345 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 88 · Phase 3 73 · Phase 4 49
First in 1996; this study’s year is marked. 18 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 74 across the 307 interventional studies, 101 across the 32 observational. Of the 281 that completed or were terminated, 136 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
170 of 345 have an industry lead sponsor. The 10 most frequent:
Glycyx Therapeutics is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Glycyx Therapeutics has 5 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
19 of the studies in Constipation with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07382167Phase 3ArdelyxA 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | 2027-02-26 |
| NCT05519683Phase 3University of MichiganHome Transcutaneous Electrical Acustimulation (TEA) | 2027-03 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06460038Cedar Valley Digestive Health CenterTenapanor in Synucleinopathy-Related Constipation | 2026-12 |
| NCT05465629ViomeViome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions | 2026-12 |
Add all 19 to your calendar (.ics) → With an account.
Among the 345 studies in Constipation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the way in which TD-1211 is absorbed and eliminated by the body and to evaluate whether it is safe and well tolerated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TD-1211 Dose 1
Drug: TD-1211 Dose 1
TD-1211 Dose 2
Drug: TD-1211 Dose 2
Cmax
Time frame: 0-96 hours
AUCt
Time frame: Based on samples collected 0-96 hours
AUCinf
Time frame: Based on samples collected 0-96 hours
Number of patients with treatment-emergent adverse events
Time frame: Days 1-14
Number patients with abnormal vital sign measurements
Time frame: Days 1-5
Number of patients with abnormal clinical laboratory results
Time frame: Days 1-5
Number of patients with abnormal corrected QTc interval
Time frame: Days 1-5
The record gives a start of Aug 2012, a primary completion of Feb 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axelopran
Glycyx Therapeutics